Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01.12.2020 | Correction

Correction to: Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways

verfasst von: Zhiyan Hu, Ting Long, Yidan Ma, Jiaxian Zhu, Lingfang Gao, Yan Zhong, Xia Wang, Xiaoyan Wang, Zuguo Li

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Zhiyan Hu and Ting Long contributed equally to this work.
The original article can be found online at https://​doi.​org/​10.​1186/​s13046-020-01578-y.
Correction to: J Exp Clin Cancer Res 39, 76 (2020)
https://doi.org/10.1186/s13046-020-01578-y
Following publication of the original article [1], the authors identified an error in the author author’s affiliation.
The incorrect author’s affiliation is:
Zhiyan Hu1,2,3†, Ting Long2,3†, Yidan Ma2,3, Jiaxian Zhu2,3, Lingfang Gao 2,3, Yan Zhong 2,3, Xia Wang 1,2,3, Xiaoyan Wang 1,2,3, Zuguo Li 4,5,6*
1 Department of Pathology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
2 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
3 Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
4 Guangdong Provincial Key Laboratory of Molecular tumor Pathology, Guangzhou, China.
5 Department of Pathology, School of Basic Medical Sciences, Southern Medical University,
6 Guangdong Provincial Key Laboratory of Molecular tumor Pathology, Guangzhou, China.
The correct author’s affiliation is:
Zhiyan Hu2,3,4†, Ting Long3,4†, Yidan Ma3,4, Jiaxian Zhu3,4, Lingfang Gao3,4, Yan Zhong3,4, Xia Wang2,3,4, Xiaoyan Wang2,3,4 and Zuguo Li1,3,4*
1 Department of Pathology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
2 Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
3 Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
4 Guangdong Provincial Key Laboratory of Molecular tumor Pathology, Guangzhou, China.
The author group has been updated above and the original article [1] has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Hu, et al. Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways. J Exp Clin Cancer Res. 2020;39:76.CrossRef Hu, et al. Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways. J Exp Clin Cancer Res. 2020;39:76.CrossRef
Metadaten
Titel
Correction to: Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways
verfasst von
Zhiyan Hu
Ting Long
Yidan Ma
Jiaxian Zhu
Lingfang Gao
Yan Zhong
Xia Wang
Xiaoyan Wang
Zuguo Li
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2020
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01635-6

Weitere Artikel der Ausgabe 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.